SHH De Novo Completed Dosing of First Patient in the US in Phase I Clinical Study for Novel TLR8 agonist DN1508052
Source: Date:2019-09-18
Shanghai De Novo Pharmatech announced achievement of important First-in-Human milestone in the US in Phase I Trials with the novel investigational TLR8 agonist DN1508052. The Phase I open-label, multi-center study is designed to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of DN1508052 in US patients with advanced solid tumors and to determine the recommended Phase II dose in these patients (www.clinicaltrials.gov identifier NCT03934359).
沪公网安备 31011502005675号